Market Access News | pharmaphorum

News

NICE backs first ophthalmic bevacizumab for NHS use

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related m

News

Incyte blocks US launch of Sun Pharma's alopecia drug

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

News

three scientists in white coats in a laboratory

Accord will build £50m manufacturing plant in UK

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the construction of a new medicines manufacturing facility.

News

Lexicon's type 1 diabetes drug voted down by FDA adcomm

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.

News

NICE trumpets new standard for health AI evaluations

With artificial intelligence technologies for healthcare on the rise, UK health technology assessment (HTA) agency NICE has published an economic evaluation standard that it says will help

News

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on

NICE backs first ophthalmic bevacizumab for NHS use

Incyte blocks US launch of Sun Pharma's alopecia drug

Accord will build £50m manufacturing plant in UK

Lexicon's type 1 diabetes drug voted down by FDA adcomm

NICE trumpets new standard for health AI evaluations

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks